Priveterra Acquisition filed with the SEC to offer 20 million units at $10 each to raise $200 million in an IPO.
The SPAC intends to target a business in the medical technology sector.
Priveterra is led by Chairman and CEO Robert Palmisano, who has more than 40 years of experience in various sectors within the healthcare industry, according to the SPAC’s S-1 filing.
Priveterra plans to list on the Nasdaq under PMGMU. Read more.
